MCID: TRP003
MIFTS: 24

Triple-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Triple-Receptor Negative Breast Cancer

MalaCards integrated aliases for Triple-Receptor Negative Breast Cancer:

Name: Triple-Receptor Negative Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060081

Summaries for Triple-Receptor Negative Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors.

MalaCards based summary : Triple-Receptor Negative Breast Cancer is related to breast cancer and ovarian epithelial cancer. An important gene associated with Triple-Receptor Negative Breast Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Pembrolizumab and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and kidney.

Related Diseases for Triple-Receptor Negative Breast Cancer

Diseases related to Triple-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 breast cancer 10.5
2 ovarian epithelial cancer 10.1 HOTAIR MALAT1
3 pituitary adenoma 10.1 HOTAIR MALAT1
4 laryngeal squamous cell carcinoma 10.0 HOTAIR MALAT1
5 pancreatic ductal adenocarcinoma 10.0 HOTAIR MALAT1
6 gastrointestinal system cancer 10.0 HOTAIR MALAT1
7 kidney cancer 10.0 HOTAIR MALAT1
8 osteogenic sarcoma 10.0 HOTAIR MALAT1
9 small cell cancer of the lung 10.0 HOTAIR MALAT1
10 oral squamous cell carcinoma 10.0 HOTAIR MALAT1
11 bladder urothelial carcinoma 10.0 HOTAIR MALAT1
12 b-cell lymphomas 10.0 HOTAIR MALAT1
13 liver cirrhosis 10.0 HOTAIR MALAT1
14 myeloma, multiple 10.0 HOTAIR MALAT1
15 retinoblastoma 9.9 HOTAIR MALAT1
16 thyroid cancer, nonmedullary, 1 9.8 HOTAIR LINC-ROR MALAT1
17 gallbladder cancer 9.8 HOTAIR LINC-ROR MALAT1
18 adamantinoma of long bones 9.8 HOTAIR LINC-ROR MALAT1
19 renal cell carcinoma, nonpapillary 9.8 HOTAIR LINC-ROR MALAT1
20 nasopharyngeal carcinoma 9.8 HOTAIR LINC-ROR MALAT1
21 lung cancer susceptibility 3 9.8 HOTAIR LINC-ROR MALAT1
22 melanoma 9.8 HOTAIR LINC-ROR MALAT1
23 pre-eclampsia 9.8 HOTAIR MALAT1
24 esophageal cancer 9.8 HOTAIR LINC-ROR MALAT1
25 pancreatic cancer 9.8 HOTAIR LINC-ROR MALAT1
26 ovarian cancer 9.8 HOTAIR LINC-ROR MALAT1
27 gastric cancer 9.7 HOTAIR LINC-ROR MALAT1
28 hepatocellular carcinoma 9.7 HOTAIR LINC-ROR MALAT1
29 lung cancer 9.6 HOTAIR LINC-ROR MALAT1 PCAT6

Graphical network of the top 20 diseases related to Triple-Receptor Negative Breast Cancer:



Diseases related to Triple-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Triple-Receptor Negative Breast Cancer

Drugs & Therapeutics for Triple-Receptor Negative Breast Cancer

Drugs for Triple-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4
Everolimus Approved Phase 2 159351-69-6 6442177
5
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
6
Fluorouracil Approved Phase 2 51-21-8 3385
7
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
8
Epirubicin Approved Phase 2 56420-45-2 41867
9
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
10
Gemcitabine Approved Phase 2 95058-81-4 60750
11
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
12
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
13
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
14
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
15 Antineoplastic Agents, Alkylating Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 Antifungal Agents Phase 2
18 Alkylating Agents Phase 2
19 Topoisomerase Inhibitors Phase 2
20 Antibiotics, Antitubercular Phase 2
21 Immunologic Factors Phase 2
22 Antimitotic Agents Phase 2
23 Anti-Bacterial Agents Phase 2
24 Anti-Infective Agents Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Antirheumatic Agents Phase 2
27 Immunosuppressive Agents Phase 2
28 Albumin-Bound Paclitaxel Phase 2
29 Antimetabolites Phase 2
30 Angiogenesis Modulating Agents Phase 2
31 Angiogenesis Inhibitors Phase 2
32 Antibodies, Monoclonal Phase 2
33 Antibodies Phase 2
34 Mitogens Phase 2
35 Immunoglobulins Phase 2
36 Protein Kinase Inhibitors Phase 2
37
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
38 taxane Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
2 Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer Unknown status NCT00499603 Phase 2 Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
3 EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Completed NCT00448305 Phase 2 EndoTAG-1 + paclitaxel;EndoTAG-1;Paclitaxel
4 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed NCT00246571 Phase 2 SU011248;Chemotherapy
5 Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer Recruiting NCT03692689 Phase 2
6 Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Not yet recruiting NCT03756298 Phase 2 Atezolizumab;Capecitabine
7 Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer Terminated NCT00739063 Phase 2 Tarceva
8 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated NCT02299635 Phase 2 PF-03084014;PF-03084014;PF-03084014

Search NIH Clinical Center for Triple-Receptor Negative Breast Cancer

Genetic Tests for Triple-Receptor Negative Breast Cancer

Anatomical Context for Triple-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Triple-Receptor Negative Breast Cancer:

41
Lymph Node, Lung, Kidney, Liver, Bone, Thyroid, B Cells

Publications for Triple-Receptor Negative Breast Cancer

Articles related to Triple-Receptor Negative Breast Cancer:

(show all 12)
# Title Authors Year
1
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. ( 29235566 )
2018
2
The unmet need for effective treatment of triple-receptor negative breast cancer. ( 25768894 )
2014
3
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. ( 23810431 )
2013
4
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. ( 21800293 )
2012
5
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. ( 22359359 )
2012
6
Triple receptor-negative breast cancer: imaging and clinical characteristics. ( 22826413 )
2012
7
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. ( 27958045 )
2011
8
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. ( 21233401 )
2011
9
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? ( 20580045 )
2010
10
Survival among women with triple receptor-negative breast cancer and brain metastases. ( 19150943 )
2009
11
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. ( 19047281 )
2009
12
Advances in triple receptor-negative breast cancer. ( 18277956 )
2007

Variations for Triple-Receptor Negative Breast Cancer

Expression for Triple-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Triple-Receptor Negative Breast Cancer.

Pathways for Triple-Receptor Negative Breast Cancer

Pathways related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR LINC-ROR

GO Terms for Triple-Receptor Negative Breast Cancer

Sources for Triple-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....